Gurgaon Samachar

The Follicular Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Follicular Lymphoma Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Follicular Lymphoma Market.

Some of the key takeaways from the Follicular Lymphoma Pipeline Report:

• Companies across the globe are diligently working toward developing novel Follicular Lymphoma treatment therapies with a considerable amount of success over the years. 
• Follicular Lymphoma companies working in the treatment market are InnoCare Pharma, Allogene Therapeutics, HUTCHMED, Sound Biologics, Xynomic Pharmaceuticals, AstraZeneca, Dr Reddy’s Laboratories, MAB WORKS, MEI Pharma, Incyte corporation, Genentech, TG Therapeutics, ADC Therapeutics, and others, are developing therapies for the Follicular Lymphoma treatment 

• Emerging Follicular Lymphoma therapies in the different phases of clinical trials are- ICP 248, ALLO-501, HMPL-689, PSB 202, Abexinostat, Acalabrutinib, DRL_RI, MIL62, Zandelisib, Tafasitamab, Mosunetuzumab, Ublituximab, Loncastuximab tesirine, and others are expected to have a significant impact on the Follicular Lymphoma market in the coming years.   
• In June 2023, In TRANSCEND clinical trials, presented at ICML 2023 on June 17th, Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) provided profound and long-lasting responses in relapsed or refractory follicular lymphoma and mantle cell lymphoma
• In June 2021, A multi-center, open label, Phase III research was started by Beijing Mabworks Biotech Co., Ltd. to compare the effectiveness and safety of MIL62 + lenalidomide and lenalidomide alone in patients with follicular lymphoma that was resistant to rituximab. Efficacy and safety of MIL62 coupled lenalidomide and lenalidomide alone in treating patients with follicular lymphoma (FL) who are resistant to rituximab are being compared in this phase III trial
• In October 2021, For Kymriah®, which is used to treat patients with relapsed or refractory follicular lymphoma, Novartis got priority review from the US FDA and filing approval from the EMA
• For the treatment of follicular lymphoma and other B-cell malignancies, zandelisib is an oral, selective PI3K delta (PI3K) inhibitor. In collaboration with Kyowa Kirin Co., Ltd., zandelisib is being developed and is set to be commercialised. In the US, MEI and KKC will jointly develop and market zandelisib, with MEI keeping track of all sales proceeds. Outside of the US, KKC owns sole commercialization rights
• In November 2021, The US Food and medication Administration (FDA) approved zandelisib as an orphan medication to treat follicular lymphoma

Follicular Lymphoma Overview

Non-Hodgkin lymphoma (NHL), often known as follicular lymphoma (FL), is a B-cell lymphoma that normally grows slowly or indolently. Of all NHL cases, this lymphoma subtype accounts for 20–30% of them.The majority of the time, follicular lymphoma is seen as a chronic condition rather than a treatable illness.

Get a Free Sample PDF Report to know more about Follicular Lymphoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/follicular-lymphoma-pipeline-insight

Emerging Follicular Lymphoma Drugs Under Different Phases of Clinical Development Include:

• ICP 248: InnoCare Pharma
• ALLO-501: Allogene Therapeutics
• HMPL-689: HUTCHMED
• PSB 202: Sound Biologics
• Abexinostat: Xynomic Pharmaceuticals
• Acalabrutinib: AstraZeneca
• Epcoritamab: Genmab A/S
• Zanubrutinib – BeiGene
• Pembrolizumab: Merck & Co.
• DRL_RI: Dr Reddy’s Laboratories
• MIL62: MAB WORKS
• Zandelisib: MEI Pharma
• Tafasitamab: Incyte corporation
• Mosunetuzumab: Genentech
• Ublituximab: TG Therapeutics
• Loncastuximab tesirine: ADC Therapeutics

Route of Administration

Follicular Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule

Follicular Lymphoma Pipeline Therapeutics Assessment

• Follicular Lymphoma Assessment by Product Type
• Follicular Lymphoma By Stage and Product Type
• Follicular Lymphoma Assessment by Route of Administration
• Follicular Lymphoma By Stage and Route of Administration
• Follicular Lymphoma Assessment by Molecule Type
• Follicular Lymphoma by Stage and Molecule Type

DelveInsight’s Follicular Lymphoma Report covers around 50+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Follicular Lymphoma product details are provided in the report. Download the Follicular Lymphoma pipeline report to learn more about the emerging Follicular Lymphoma therapies

Some of the key companies in the Follicular Lymphoma Therapeutics Market include:

Key companies developing therapies for Follicular Lymphoma are – Merck & Co, Genentech, Incyte Corporation, Syndax Pharmaceuticals, Dr Reddy’s Laboratories, Novartis, ADC Therapeutics, Xynomic Pharmaceuticals, Cho Pharma Inc., Janssen, XEME Biopharma Inc., Shanghai Yingli Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Beijing Mabworks Biotech Co., Ltd., Archigen Biotech, Hutchison Medipharma Limited, Nordic Nanovector, Xynomic Pharmaceuticals, TG Therapeutics, BeiGene, Allogene Therapeutics, MEI Pharma, Inc., Pfizer, Innovent Biologics (Suzhou) Co. Ltd., Enterome, AstraZeneca, Nanjing Sanhome Pharmaceutical, Co., Ltd., Takeda, Bristol-Myers Squibb, TCR2 Therapeutics, and others.

Follicular Lymphoma Pipeline Analysis:

The Follicular Lymphoma pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Follicular Lymphoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Follicular Lymphoma Treatment.
• Follicular Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Follicular Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Follicular Lymphoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Follicular Lymphoma drugs and therapies

Follicular Lymphoma Pipeline Market Drivers

• Increase in prevalence of Follicular Lymphoma, emergence of effective novel therapies, increased Research and Developmental Activities are some of the important factors that are fueling the Follicular Lymphoma Market.

Follicular Lymphoma Pipeline Market Barriers

• However, lack Of Cost-Effective Treatment, progression of disease within 2 years (POD24) in the Disease and other factors are creating obstacles in the Follicular Lymphoma Market growth.

Scope of Follicular Lymphoma Pipeline Drug Insight    

• Coverage: Global
• Key Follicular Lymphoma Companies: InnoCare Pharma, Allogene Therapeutics, HUTCHMED, Sound Biologics, Xynomic Pharmaceuticals, AstraZeneca, Dr Reddy’s Laboratories, MAB WORKS, MEI Pharma, Incyte corporation, Genentech, TG Therapeutics, ADC Therapeutics, and others
• Key Follicular Lymphoma Therapies: ICP 248, ALLO-501, HMPL-689, PSB 202, Abexinostat, Acalabrutinib, DRL_RI, MIL62, Zandelisib, Tafasitamab, Mosunetuzumab, Ublituximab, Loncastuximab tesirine, and others
• Follicular Lymphoma Therapeutic Assessment: Follicular Lymphoma current marketed and Follicular Lymphoma emerging therapies
• Follicular Lymphoma Market Dynamics: Follicular Lymphoma market drivers and Follicular Lymphoma market barriers 

Request for Sample PDF Report for Follicular Lymphoma Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services